Skip to content
HowShorted

Viking Therapeutics, Inc. short interest in 2021

In 2021, Viking Therapeutics, Inc.'s disclosed short interest ran from 12.04% of shares outstanding on 15 Jan 2021 to 4.68% on 31 Dec 2021, a change of -7.36 percentage points. The year's high was 14.21% on 15 Apr 2021 and its low 4.68% on 31 Dec 2021, averaging 9.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.93 days on 15 Apr 2021. Full history: Viking Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viking Therapeutics, Inc. in 2021

2021 in figures

Start of year
12.04% (15 Jan 2021)
End of year
4.68% (31 Dec 2021)
Change
-7.36 pp
High
14.21% (15 Apr 2021)
Low
4.68% (31 Dec 2021)
Average
9.82%
Highest days to cover
14.93 (15 Apr 2021)
SEC filings marked
8

Every report in 2021

Viking Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202112.04%7.64
29 Jan 202111.60%5.22
12 Feb 202111.17%4.03
26 Feb 202111.36%6.4310-K filed, results (8-K)
15 Mar 202111.49%8.19
31 Mar 202113.56%9.68
15 Apr 202114.21%14.93
30 Apr 202113.56%13.6810-Q filed, results (8-K)
14 May 202113.79%12.96
28 May 202113.00%10.34
15 Jun 202112.67%9.95
30 Jun 202110.42%6.05
15 Jul 202110.09%11.63
30 Jul 202110.38%13.9110-Q filed, results (8-K)
13 Aug 20219.43%12.78
31 Aug 20218.15%9.09
15 Sep 20217.50%8.35
30 Sep 20216.49%8.15
15 Oct 20216.08%10.25
29 Oct 20216.36%8.83
15 Nov 20216.11%7.0110-Q filed, results (8-K)
30 Nov 20216.31%7.88
15 Dec 20215.31%4.10
31 Dec 20214.68%4.86

See also: Viking Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.